The final close was led by Ackermans & van Haaren, with participation from additional new investors AbbVie Ventures and M Ventures, alongside existing investors Bioqube Ventures, Korys and Novo Holdings.Funds will take first development candidate COM002 into the clinic, advance a second program into IND-enabling development and expand the BiCE™ pipeline.Michael Rosenzweig (AbbVie Ventures), Charlotte Kremers (M Ventures) and Lenny Van Steenhuyse (Ackermans & van Haaren) join the Board of Directors.
COPENHAGEN, Denmark, November 17, 2026 — Commit Biologics (“Commit”), the biotechnology company pioneering complement-powered immune engagers, today announced the completion of a $60 million (€54 million) seed financing round to advance its pipeline of complement-powered immune engagers toward the clinic. The final close was led by Ackermans & van Haaren, with participation from additional new investors AbbVie Ventures and M Ventures, and existing investors Bioqube Ventures, Korys and Novo Holdings.
Proceeds from the financing will support the completion of IND-enabling activities and IND filing for COM002, Commit’s first development candidate, which was announced last week. COM002 is a dual-targeting Bispecific Complement Engager (BiCE™) molecule designed for targeted immune cell depletion, developed for patients with cancer and autoimmune disease. Additionally, the financing will advance a second program into IND-enabling development and expand Commit’s BiCE™ pipeline.
Commit was founded on a simple idea: that complement, one of the most powerful parts of our immune system, could be deliberately directed against diseased cells. With this financing, we will take COM002, a first-in-class immune engager that works independently of T cells, into the clinic and build the foundation for complement-powered immune engagers to become a new pillar of immunotherapy.
He added: “Seeing our first development candidate backed by such a strong group of financial and strategic investors is a proud moment for the whole team.”
Complement is among the immune system’s most potent effector mechanisms yet remains largely untapped in drug development. Commit has made it programmable in a standard antibody, creating a path to medicines with differentiated efficacy and safety profiles across indications.
We firmly believe that Commit’s novel drug platform has the potential to generate a new treatment paradigm in immunotherapy based on the highly compelling preclinical data in targeted cell depletion. Ackermans & van Haaren is proud to support the Commit team and lead this financing to realize the full potential of the BiCE™ platform.